The hospital would then offer these patients Leqvio to prevent further heart problems, in a process more akin to a vaccine drive than a drug launch. Novartis expects to finalize agreements after the Food and Drug Administration completes its review of Leqvio, which the company expects early next year. Some health systems already take this so-called population health approach. Geisinger insures around half of the patients that it treats, creating a financial incentive, on top of the clinical rationale, for cutting emergency admissions.
The drug targets a type of cholesterol known as low-density lipoprotein, or LDL, the sort that can clog up blood vessels and increase the risk of heart attacks and strokes. Around 20 million people in the U. In recent years, new injectable LDL-lowering drugs have also hit the market. Despite the widespread availability of statins, which cost pennies a day, most people struggle to lower their LDL. Less than half of all people using statins cut their cholesterol to the recommended level after two years of treatment, according to a large U.
One reason: it is hard to stick to a daily pill for an invisible ailment. Novartis hopes Leqvio can overcome this problem because it is delivered by an injection twice a year and could be administered during routine heart checkups. Leqvio is also more powerful than statins. In two major clinical trials on patients with a heart problem related to high cholesterol, it cut LDL levels in half when taken on top of statins.
In the placebo group, most of whom were taking statins, cholesterol levels rose slightly. Even so, some cardiologists may remain reluctant to widely prescribe Leqvio without hard evidence that it reduces heart attacks and strokes. Leqvio will compete against two similar drugs that have been on the market for a few years, and have already proven that they reduce the risk of heart attack and stroke.
Pay based on use. Does my organisation subscribe? Group Subscription. Premium Digital access, plus: Convenient access for groups of users Integration with third party platforms and CRM systems Usage based pricing and volume discounts for multiple users Subscription management tools and usage reporting SAML-based single sign-on SSO Dedicated account and customer success teams. Learn more and compare subscriptions content expands above. Full Terms and Conditions apply to all Subscriptions.
Or, if you are already a subscriber Sign in. Other options. Premium Digital access, plus: Convenient access for groups of users Integration with third party platforms and CRM systems Usage based pricing and volume discounts for multiple users Subscription management tools and usage reporting SAML-based single sign-on SSO Dedicated account and customer success teams.
Learn more and compare subscriptions content expands above. Full Terms and Conditions apply to all Subscriptions. Or, if you are already a subscriber Sign in. Other options. Close drawer menu Financial Times International Edition. Search the FT Search. World Show more World.
0コメント